Partridge Andrew John
- SEC CIK
- 0001758838
In the past year, 1 open-market sale filing worth $91.1K and no purchases.
Current role at each company
- GRAL GRAIL, Inc.Chief Growth Officeras of Jun 5, 2026
- TPTX Turning Point Therapeutics, Inc.EVP & Chief Commercial Officeras of Feb 11, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $91.1K
- 1 filing
- Net
- −$91.1K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Partridge Andrew John as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
GRAL GRAIL, Inc.
Chief Growth Officer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 5, 2026 (view filing) | Jun 4 | 1 day | Partridge Andrew JohnChief Growth Officer | SSale | −1.49K | $61.08 | −$91.1K | −0.9%163.7K after |
TPTX Turning Point Therapeutics, Inc.
EVP & Chief Commercial Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Partridge Andrew JohnEVP & Chief Commercial Officer | SSale | −221 | $36.30 | −$8.02K | −1.0%22.1K after | |
| Jul 15, 2021 (view filing) | Jul 14 | 1 day | Partridge Andrew JohnEVP & Chief Commercial Officer | SSale | −1.87K | $74.90 | −$140.0K | −7.9%21.8K after |